iCo Therapeutics is a Canada-based biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat sight-and life-threatening diseases. Its business model aims to acquire the rights to drugs that are either off-patent, currently approved or near commercialization and develop them. The company's product candidates include iCo-007, iCo-008 and an Oral Amphotericin B (Amp B) Delivery System.